• Briacell Therapeutics announced new clinical updates for its Bria-IMT immunotherapy program in metastatic breast cancer, with results already presented from a completed Phase 2 study and additional data slated for presentation at the ASCO 2026 meeting from May 29 to June 2, 2026.
• Final Phase 2 readouts indicated patients lived longer when the regimen was started earlier and when blood-based indicators suggested a stronger immune response, supporting the company’s Phase 3 dosing and treatment approach.
• Early, blinded Phase 3 patient-reported outcomes indicated quality of life was largely maintained in a heavily pretreated population, with tolerability consistent with outpatient use and potential for decentralized administration.
• An ongoing Phase 3 biomarker analysis linked early stabilization in blood-based markers with improved disease control, a signal the company is using to support its strategy to identify likely responders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605220730PRIMZONEFULLFEED9725039) on May 22, 2026, and is solely responsible for the information contained therein.